| Literature DB >> 27460962 |
Rui-Ping Pang1, Man-Xiu Xie2, Jie Yang2, Kai-Feng Shen2, Xi Chen3, Ying-Xue Su4, Chao Yang5, Jing Tao6, Si-Jia Liang6, Jia-Guo Zhou7, He-Quan Zhu2, Xu-Hong Wei2, Yong-Yong Li2, Zhi-Hai Qin8, Xian-Guo Liu9.
Abstract
ClC-3 chloride channel/antiporter has been demonstrated to play an important role in synaptic transmission in central nervous system. However, its expression and function in sensory neurons is poorly understood. In present work, we found that ClC-3 is expressed at high levels in dorsal root ganglia (DRG). Co-immunofluorescent data showed that ClC-3 is mainly distributed in A- and C-type nociceptive neurons. ClC-3 expression in DRG is decreased in the spared nerve injury (SNI) model of neuropathic pain. Knockdown of local ClC-3 in DRG neurons with siRNA increased mechanical sensitivity in naïve rats, while overexpression of ClC-3 reversed the hypersensitivity to mechanical stimuli after peripheral nerve injury. In addition, genetic deletion of ClC-3 enhances mouse mechanical sensitivity but did not affect thermal and cold threshold. Restoration of ClC-3 expression in ClC-3 deficient mice reversed the mechanical sensitivity. Mechanistically, loss of ClC-3 enhanced mechanical sensitivity through increasing the excitability of DRG neurons. These data indicate that ClC-3 is an endogenous inhibitor of neuropathic pain development. Downregulation of ClC-3 by peripheral nerve injury is critical for mechanical hypersensitivity. Our findings suggest that ClC-3 is a novel therapeutic target for treating neuropathic pain.Entities:
Keywords: ClC-3; Dorsal root ganglia; Mechanical hypersensitivity; Neuropathic pain; Peripheral nerve injury
Mesh:
Substances:
Year: 2016 PMID: 27460962 DOI: 10.1016/j.neuropharm.2016.07.023
Source DB: PubMed Journal: Neuropharmacology ISSN: 0028-3908 Impact factor: 5.250